Business, energy, technology, markets and global industry news from Business News Today

HER2

PharmaDeviceNews HER2
Representative image: Gastric cancer imaging and biomarker analysis illustrate ALX Oncology’s evorpacept results in HER2-positive, CD47-high tumors from the ASPEN-06 study.
Pharma & Biotech

Evorpacept biomarker signal deepens in HER2-positive gastric cancer as ALX Oncology shifts focus

ALX Oncology’s evorpacept raises response to 63.6% in a HER2-retained, CD47-high gastric cancer subgroup, supporting biomarker-led development.

Read More
Representative image: Clinicians review lung cancer genomic testing data and blood-based diagnostic results, reflecting Guardant Health’s Guardant360 CDx FDA approval as a companion diagnostic for HERNEXEOS in HER2-mutant advanced non-small cell lung cancer.
Medical Devices & Diagnostics

How Guardant360 CDx approval supports Boehringer Ingelheim’s HERNEXEOS launch strategy

Find out how Guardant360 CDx approval could expand liquid biopsy use in HER2-mutant advanced lung cancer treatment selection.

Read More
Pharma & Biotech

How Celltrion’s HER2–CD3 bispecific could compete in the T-cell engager arena

Celltrion is going all-in on oncology biologics with ADCs, msAbs, and U.S. biomanufacturing scale-up. Find out what this shift means for global competition.

Read More